Actinogen Medical Ltd (ACW)

Sydney
0.070
-0.008(-10.26%)
  • Volume:
    1,207,143
  • Bid/Ask:
    0.070/0.076
  • Day's Range:
    0.070 - 0.078

ACW Overview

Prev. Close
0.078
Day's Range
0.07-0.078
Revenue
20K
Open
0.078
52 wk Range
0.055-0.198
EPS
0
Volume
1,207,143
Market Cap
135.25M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
2,001,897
P/E Ratio
-
Beta
1.21
1-Year Change
8.57%
Shares Outstanding
1,779,643,817
Next Earnings Date
28 Aug 2022
What is your sentiment on Actinogen Medical?
or
Market is currently closed. Voting is open during market hours.

Actinogen Medical Ltd News

Actinogen Medical Ltd Company Profile

Actinogen Medical Ltd Company Profile

Employees
6
Market
Australia

Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in developing treatment for cognitive impairment associated with neurological diseases of raised cortisol levels inside brain cells. The Company's lead drug candidate, Xanamem, has been designed to block the production of cortisol the stress hormone in the brain. Xanamem is a unique inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the central nervous system. It is an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in neuropsychiatric diseases. The Company focuses on developing Phase II clinical trial evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • will it keep going?
    0